ライフサイエンスコーパス: PMRT

1 PMRT after a diagnosis of BC sharply increased the risk

2 PMRT can lead to an increased frequency of complications

3 PMRT increased 15-year costs from $40,800 to $48,100.

4 PMRT is associated with improved survival for older wome

5 PMRT should not be routinely used for these patients.

6 We hypothesized that (1) PMRT rates would increase for women affected by the revi

7 Although PMRT is currently recommended for patients with four or

8 d the joint effects of cigarette smoking and PMRT on LC risk.

9 independent and joint effects of smoking and PMRT on risk of overall, ipsilateral, and contralateral

10 ratios for the joint effects of smoking and PMRT were 10.5 (95% CI, 2.9 to 37.8) for the contralater

11 Smoking and PMRT were associated with increased risk for all histolo

12 The relationship between PMRT and mortality was determined using proportional haz

13 only, and 59% for patients treated with both PMRT and chemotherapy.

14 For women with T1-2 breast cancer, PMRT is associated with a 15% to 20% relative reduction

15 counseling clinicians to "strongly consider" PMRT for patients with breast cancer with tumors 5 cm or

16 After adjusting for covariates, PMRT use was not associated with mortality (hazard ratio

17 Patients and Methods We delivered PMRT at a dose of 36.63 Gy in 11 fractions of 3.33 Gy ov

18 However, the interaction term for PMRT use and number of involved regional lymph nodes was

19 of involved nodes, a mortality benefit from PMRT may exist.

20 ncrease risk of complications resulting from PMRT.

21 evaluated a short course of hypofractionated PMRT, in which therapy was completed in 15 treatment day

22 Data supporting hypofractionated PMRT is limited.

23 rial of conventional versus hypofractionated PMRT that will activate soon.

24 nes have been associated with an increase in PMRT among patients with tumors 5 cm or smaller and 1 to

25 or without adjuvant systemic therapy and no PMRT, LRF as first event remains low.

26 The addition of PMRT reduced the risk of disease relapse by an odds rati

27 o 3 positive nodes; however, anticipation of PMRT may lead to delay or omission of reconstruction, wh

28 low risk of LRF that the absolute benefit of PMRT is outweighed by its potential toxicities.

29 women age 70 years or older, the benefits of PMRT are unknown.

30 ith patients about the risks and benefits of PMRT.

31 Costs of PMRT ($11,600) and recurrent breast cancer ($4,250 to 16

32 study offers one of the shortest courses of PMRT reported, delivered in 11 fractions to the chest wa

33 Rates of PMRT were unchanged in the radiotherapy recommended (29.

34 is to evaluate temporal trends in receipt of PMRT and breast reconstruction.

35 Receipt of PMRT for the strongly consider radiotherapy cohort was u

36 We sought to study the receipt of PMRT in elderly women in this period, using a population

37 Despite increasing receipt of PMRT, the strongly consider radiotherapy cohort maintain

38 The benefits and risks of PMRT in such patients, as well as subgroups of these pat

39 The use of PMRT in elderly women increased significantly during the

40 The use of PMRT significantly increased in women diagnosed in 1996

41 association of diagnosis year and the use of PMRT, after controlling for clinical and sociodemographi

42 rapy in this group of patients, the value of PMRT remains unknown.

43 For high-risk patients, PMRT was associated with a significant improvement in su

44 For low- and intermediate-risk patients, PMRT was not associated with survival.

45 have found that postmastectomy radiotherapy (PMRT) for breast cancer (BC) increases the risk of lung

46 onstruction and postmastectomy radiotherapy (PMRT) has increased over the past decade, the typical ap

47 ncerning use of postmastectomy radiotherapy (PMRT).

48 o 12.8) for ever-smokers who did not receive PMRT and 18.9 (95% CI, 7.9 to 45.4) for ever-smokers who

49 ed with nonsmoking women who did not receive PMRT, nonsmoking women who received PMRT had no higher r

50 panel recommends that these patients receive PMRT only if there is already sufficient information to

51 neoadjuvant systemic therapy should receive PMRT.

52 Only 2,648 women (15%) received PMRT.

53 %) patients treated with mastectomy received PMRT.

54 5 (38%) of 2,053 high-risk patients received PMRT.

55 receive PMRT, nonsmoking women who received PMRT had no higher risk of LC; adjusted odds ratios were

56 , 7.9 to 45.4) for ever-smokers who received PMRT.

57 Thus, the decision to recommend PMRT requires a great deal of clinical judgment.

58 matched case-control analysis confirmed that PMRT was associated with reduced mortality only in the s

59 ly agreed that available evidence shows that PMRT reduces the risks of locoregional failure (LRF), an

60 This analysis suggests that PMRT offers substantial clinical benefits achieved in a

61 The details of the PMRT technique were also evaluated.

62 of use of postmastectomy radiation therapy (PMRT) during the period of information dissemination reg

63 iveness of postmastectomy radiation therapy (PMRT) have led to changes in National Comprehensive Canc

64 icate that postmastectomy radiation therapy (PMRT) improves survival for women age younger than 70 ye

65 actionated postmastectomy radiation therapy (PMRT) takes approximately 5 to 6 weeks.

66 nd without postmastectomy radiation therapy (PMRT).

67 en reconstruction should be done relative to PMRT and whether radiotherapy treatment should be direct

68 older women, we sought to determine whether PMRT improves survival for older women with breast cance

69 linical-pathologic covariates tested whether PMRT was associated with improved overall survival for l

70 survival was increased from 48% to 55% with PMRT, resulting in an incremental 0.29 years of life gai

71 th seven or more involved nodes treated with PMRT experienced a significant reduction in all-cause (H

72 chemotherapy, 56% for patients treated with PMRT only, 57% for patients treated with chemotherapy on

73 rvival was 50% for patients not treated with PMRT or chemotherapy, 56% for patients treated with PMRT

74 e of reconstruction that should be used with PMRT, when reconstruction should be done relative to PMR

75 ree survival of 52% and 43% with and without PMRT, respectively.

76 ards of local and distant recurrence without PMRT were derived from a large meta-analysis of adjuvant